Look for:

Our offer for

BIOGEN IDEC INC.


ISIN:
US09062X1037
WKN:
09062X103
2024/04/30 19:31:04
Price
202.90 EUR
Difference 0.74% (1.50)

General attributes

ISINUS09062X1037
SymbolBIIB
ExchangeDuesseldorf
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)29,504 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)-
Ask (Ask size)-
Open200.40 EUR
High202.90 EUR
Low199.85 EUR
Close (prev. day)201.40 EUR
VWAP236.76 EUR
Volume (pcs)0
Trading volume0.00
Number of trades7
Last size0

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: BIOGEN IDEC INC.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2024/04/30 19:31:04
Price
202.90 EUR
Difference 0.74% (1.50)

General attributes

ISINUS09062X1037
SymbolBIIB
ExchangeDuesseldorf
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)29,504 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)-
Ask (Ask size)-
Open200.40 EUR
High202.90 EUR
Low199.85 EUR
Close (prev. day)201.40 EUR
VWAP236.76 EUR
Volume (pcs)0
Trading volume0.00
Number of trades7
Last size0

Performance and Risk

6m1Y3Y
Perf (%)-8.77%-26.27%-9.26%
Perf (abs.)-19.50-72.30-20.70
Beta0.860.690.80
Volatility25.6223.2937.90
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

194,62 EUR (0)
191,67 EUR (0)
211,78 EUR (2)
233,19 EUR (1)
243,60 EUR (03.01.2024)
177,50 EUR (19.04.2024)
311,00 EUR (12.06.2023)
177,50 EUR (19.04.2024)

BIOGEN IDEC INC.

 
Xetra30.04.202417:35203,20 EUR0,0612
Vienna Stock Exchange30.04.202417:32203,00 EUR0,002
Tradegate30.04.202422:26201,40 EUR0,027
Stuttgart30.04.202421:54201,70 EUR0,0012
SIX Swiss Exchange28.09.202217:36222,00 CHF0,001
Nasdaq01.05.202422:00216,13 USD198,4124.068
Munich30.04.202408:00200,60 EUR0,002
London Stock Exchange29.04.202416:12217,62 USD0,007
Hanover30.04.202408:45200,70 EUR0,003
Hamburg30.04.202408:11200,70 EUR0,003
Frankfurt30.04.202415:50200,80 EUR0,003
Euronext Milan MTF Trading After Hours15.04.202418:43188,00 EUR0,002
Euronext Milan MTF Global Equity Market30.04.202417:44203,10 EUR0,001
Duesseldorf30.04.202419:31202,90 EUR0,007
Berlin30.04.202420:21200,70 EUR0,0017

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=2033&ID_TYPE_IMAGE_LOGO=2
BIOGEN INC.
- -
225 Binney Street - 02142 Cambridge
+1-617-679-2000
+
info@biogen.com
: BIOGEN IDEC INC.PDF Download

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Caroline DorsaChairman of Board of Directors
Eric RowinskyMember of Board of Directors
Maria FreireMember of Board of Directors
Stephen SherwinMember of Board of Directors
Jesus MantasMember of Board of Directors
Monish PatolawalaMember of Board of Directors
Susan LangerMember of Board of Directors
William HawkinsMember of Board of Directors
Chris ViehbacherChairman of Managing Board
Ginger GregoryMember of Executive Committee
Michael McDonnellMember of Executive Committee
Nicole MurphyMember of Executive Committee
Priya SinghalMember of Executive Committee
Rachid IzzarMember of Executive Committee
Susan H. AlexanderMember of Executive Committee






Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer